Arrive AI Celebrates 2025 Milestones
Rhea-AI Summary
Arrive AI (NASDAQ:ARAI) released its 2025 Year in Review highlighting public‑market milestones, healthcare deployments, partnerships, IP growth, and product acceleration.
Key 2025 items: Nasdaq direct listing and start of trading
Positive
- Nasdaq direct listing and trading began on May 15, 2025
- Added to Russell 2000 and Russell 3000 on Oct 20, 2025
- Authorized a $10 million share repurchase program (through Mar 31, 2026)
- Launched multi‑year healthcare deployments with Hancock Health (May 19, 2025)
- Accepted into NVIDIA Connect to accelerate software development
- Patent portfolio reached 9 issued U.S. patents (Aug 18, 2025)
Negative
- None.
News Market Reaction
On the day this news was published, ARAI declined 5.70%, reflecting a notable negative market reaction. Argus tracked a peak move of +6.4% during that session. Argus tracked a trough of -2.1% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $6M from the company's valuation, bringing the market cap to $103M at that time.
Data tracked by StockTitan Argus on the day of publication.
Nasdaq Debut, Healthcare Deployments, Global Expansion, and Accelerating Innovation
INDIANAPOLIS, INDIANA / ACCESS Newswire / January 7, 2026 / Arrive AI (NASDAQ:ARAI), the autonomous delivery network company powering secure, AI-driven delivery for healthcare and enterprise, today released its 2025 Year in Review, highlighting major public-market, product, partnership, and intellectual property milestones achieved throughout the year. arriveai.com (https://www.arriveai.com/press-releases)
"Being an early-stage company, we are hyper-focused on milestones. I can say that on every metric we track, we are pegged to the top. We are executing at the highest level. In 2026 I see a lot of strategic consolidation happening in our space, and I believe we will be at the center of that! We will be a catalyzing force in shaping the intersection of AI and Autonomy," said Dan O'Toole, Arrive AI CEO.
2025: A year of momentum across public markets, deployments, and partnerships
In 2025, Arrive AI advanced its mission to modernize the last inch of the last-mile delivery with secure, unattended exchange across people, robots, and drones-while expanding the foundation needed to scale globally.
Secured approval for a Nasdaq direct listing (May 14, 2025) and began trading on Nasdaq as ARAI (May 15, 2025).
Celebrated the Nasdaq debut, including recognition events around the listing.
Joined the Russell 2000® and Russell 3000® Indexes (Oct. 20, 2025), marking a significant public-market milestone.
Authorized a
$10 million share repurchase program (announced Sept. 8, 2025; through March 31, 2026).Healthcare traction + autonomous deployments
Launched a two-year partnership with Hancock Health to support robotic medical deliveries (May 19, 2025).
Expanded into fully asynchronous autonomous medical deliveries at Hancock Regional Hospital (Oct. 28, 2025).
Partnerships and expansion
Partnered with Go2 Delivery to advance secure medication delivery in Virginia (May 20, 2025).
Partnered with Peachtree Corners (smart-city environment) to launch secure automated delivery initiatives (June 4, 2025).
Entered India via Skye Air Mobility partnership (June 24, 2025).
Selected Synoptek as a strategic IT partner to support global expansion (July 10, 2025).
Team + operational scale
Added board leadership with the appointment of former FedEx executive Laurie Tucker (June 2, 2025).
Initiated post-Nasdaq hiring expansion (July 22, 2025).
Relocated to a new ~30,000 sq. ft. headquarters in Fishers to support growth (Nov. 10, 2025).
NVIDIA Connect: accelerating product and software development
Late in 2025, Arrive AI was accepted into the NVIDIA Connect program, enabling the company to dramatically accelerate product iteration and software development-including faster simulation workflows and improved digital modeling that compresses build-test cycles.
Patents: expanding an already-strong moat
Arrive AI's innovation engine was matched by continued investment in defensible IP. The company's patent portfolio expanded in 2025, including the issuance of the company's ninth U.S. patent (Aug. 18, 2025).
Arrive AI's IP portfolio now includes 9 issued patents and additional patents pending, along with trademarks and international filings-strengthening the company's platform advantage as autonomous delivery scales.
Looking ahead to 2026: roadmap execution at greater speed
In 2026, Arrive AI plans to build on 2025's momentum by scaling deployments, expanding enterprise and healthcare use cases, and accelerating development through NVIDIA Connect-enabled workflows. The company will also engage ecosystem partners and industry leaders at major events, including CES 2026.
For investors, Arrive AI's five-year roadmap and growth plan are detailed in the company's investor deck.
About Arrive AI
Arrive AI's patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox, whether by drone, ground robot or human courier. The platform provides real-time tracking, smart logistics alerts and advanced chain of custody controls to support shippers, delivery services and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting and security systems to streamline the entire last-mile delivery experience. Learn more at www.arriveai.com and via the company's press kit.
Media contact: Cheryl Reed, media@arriveai.com
Investor Relations Contact: Alliance Advisors IR, ARAI.IR@allianceadvisors.com
Cautionary Note Regarding Forward Looking Statements
This news release and statements of Arrive AI's management in connection with this news release or related events contain or may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements, including but not limited to statements related to the future regulatory environment applicable to Arrive AI, the prospects of hiring the desired talents, and building productive and profitable products or systems related to future events, which may impact our expected future business and financial performance, and often contain words such as "expects", "anticipates", "intends", "plans", "believes", "potential", "will", "should", "could", "would", "optimistic" or "may" and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management's current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors which may be beyond our control. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. Potential investors should review Arrive AI's filings with the United States Securities and Exchange Commission for more complete information, including the risk factors that may affect future results, which are available for review at www.sec.gov. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.
SOURCE: Arrive AI Inc.
View the original press release on ACCESS Newswire
FAQ
When did Arrive AI (ARAI) begin trading on Nasdaq?
What is the size and timeline of Arrive AI's share repurchase program (ARAI)?
How many patents did Arrive AI report by the end of 2025 (ARAI)?
What healthcare deployments did Arrive AI announce in 2025 (ARAI)?
Which strategic partnerships and geographic expansions did Arrive AI announce in 2025 (ARAI)?
How will NVIDIA Connect affect Arrive AI's product development (ARAI)?
